BeyondSpring Inc. Share Price & Technical Analysis
BYSI · $1.57 (+9.03%)
Healthcare / Biotechnology
$1.57
+9.03%
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical tr…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
0% return in May, 14% avg return in past 3 year May month.
-10% return in 2026, 33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | -7% | 14% | -6% | 0% | – | – | – | – | – | – | – | -10% |
| 25 | 13% | 0% | -18% | 21% | 0% | 28% | -17% | -15% | 6% | 11% | -9% | -24% | -3% |
| 24 | 11% | 30% | 157% | -43% | 30% | -8% | -21% | 5% | 15% | -4% | -14% | -16% | 143% |
| 23 | 37% | -24% | -42% | -9% | 11% | 9% | -17% | -10% | -11% | 25% | -10% | 0% | -41% |
| 22 | -30% | -27% | -12% | -32% | -7% | 0% | -7% | -7% | -23% | -30% | -25% | 217% | 17% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Uptrend
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$59.62M
P/E ratio
—
52W high
$3.44
52W low
$1.18
Volume
40,054
Beta
0.41
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BeyondSpring Inc. share price today?
- BeyondSpring Inc. (BYSI) last traded around $1.57 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BYSI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BYSI. Download the app for real-time alerts.
- How can I analyze BeyondSpring Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.